Profiling steroid hormone landscape of bladder cancer reveals depletion of intratumoural androgens to castration levels: a cross-sectional study.

Androgens Bladder cancer Sex steroids Steroid profile Steroidomics

Journal

EBioMedicine
ISSN: 2352-3964
Titre abrégé: EBioMedicine
Pays: Netherlands
ID NLM: 101647039

Informations de publication

Date de publication:
28 Sep 2024
Historique:
received: 13 05 2024
revised: 04 09 2024
accepted: 08 09 2024
medline: 30 9 2024
pubmed: 30 9 2024
entrez: 29 9 2024
Statut: aheadofprint

Résumé

Bladder cancer is a highly over-represented disease in males. The involvement of sex steroids in bladder carcinogenesis and the utilisation of steroid hormone action as a therapeutic target have been frequently proposed. However, the intratumoural steroid milieu remains unclear. We used mass spectrometry and transcriptomic profiling to determine the levels of 23 steroid hormones and the expression of steroidogenic enzymes in primary tumours from patients who underwent transurethral resection (n = 24), and tumours and adjacent morphologically benign bladder tissues from treatment-naïve patients, who underwent radical cystectomy (n = 20). The corresponding steroids were determined from the patients' sera. Our results show that both bladder tumours and non-tumour tissues are androgen-poor, with DHT being virtually unquantifiable and testosterone at castration levels. Intratumoural enzymes that inactivate potent androgens (e.g., HSD17B2) exhibited similar tumour aggressiveness-linked downregulation, as reported in advanced forms of classical steroid-dependent cancers, whereas there was little change in the corresponding activating enzymes. Finally, our results suggest cancer aggressiveness-linked dissimilarities in steroid profiles; the patients with overall low circulating steroid levels and those with an association between androgen receptor expression and intratumoural testosterone levels in place had fewer recurrences than the rest. By revealing the steroid landscape of bladder cancer, our study not only underscores the androgen-poor nature of the malignancy but also identifies potential alterations in steroid profiles that are linked to disease aggressiveness. The Cancer Foundation Finland, the Finnish State Research Funding (VTR).

Sections du résumé

BACKGROUND BACKGROUND
Bladder cancer is a highly over-represented disease in males. The involvement of sex steroids in bladder carcinogenesis and the utilisation of steroid hormone action as a therapeutic target have been frequently proposed. However, the intratumoural steroid milieu remains unclear.
METHODS METHODS
We used mass spectrometry and transcriptomic profiling to determine the levels of 23 steroid hormones and the expression of steroidogenic enzymes in primary tumours from patients who underwent transurethral resection (n = 24), and tumours and adjacent morphologically benign bladder tissues from treatment-naïve patients, who underwent radical cystectomy (n = 20). The corresponding steroids were determined from the patients' sera.
FINDINGS RESULTS
Our results show that both bladder tumours and non-tumour tissues are androgen-poor, with DHT being virtually unquantifiable and testosterone at castration levels. Intratumoural enzymes that inactivate potent androgens (e.g., HSD17B2) exhibited similar tumour aggressiveness-linked downregulation, as reported in advanced forms of classical steroid-dependent cancers, whereas there was little change in the corresponding activating enzymes. Finally, our results suggest cancer aggressiveness-linked dissimilarities in steroid profiles; the patients with overall low circulating steroid levels and those with an association between androgen receptor expression and intratumoural testosterone levels in place had fewer recurrences than the rest.
INTERPRETATION CONCLUSIONS
By revealing the steroid landscape of bladder cancer, our study not only underscores the androgen-poor nature of the malignancy but also identifies potential alterations in steroid profiles that are linked to disease aggressiveness.
FUNDING BACKGROUND
The Cancer Foundation Finland, the Finnish State Research Funding (VTR).

Identifiants

pubmed: 39342807
pii: S2352-3964(24)00395-5
doi: 10.1016/j.ebiom.2024.105359
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

105359

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests JM reports funding for PhD studies from the University of Turku Graduate School. Other authors declare no potential conflicts of interest.

Auteurs

Kimmo Kettunen (K)

Institute of Biomedicine and FICAN West Cancer Centre, University of Turku, Turku, Finland.

Julia Mathlin (J)

Institute of Biomedicine and FICAN West Cancer Centre, University of Turku, Turku, Finland; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.

Tarja Lamminen (T)

Department of Urology and FICAN West Cancer Centre, Turku University Hospital, and University of Turku, Turku, Finland.

Asta Laiho (A)

Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.

Merja R Häkkinen (MR)

Department of Health Security, Finnish Institute for Health and Welfare, Kuopio, Finland; School of Pharmacy, University of Eastern Finland, Kuopio, Finland.

Seppo Auriola (S)

School of Pharmacy, University of Eastern Finland, Kuopio, Finland.

Laura L Elo (LL)

Institute of Biomedicine and FICAN West Cancer Centre, University of Turku, Turku, Finland; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.

Peter J Boström (PJ)

Department of Urology and FICAN West Cancer Centre, Turku University Hospital, and University of Turku, Turku, Finland.

Matti Poutanen (M)

Institute of Biomedicine and FICAN West Cancer Centre, University of Turku, Turku, Finland; Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden; Turku Center for Disease Modeling, University of Turku, Turku, Finland.

Pekka Taimen (P)

Institute of Biomedicine and FICAN West Cancer Centre, University of Turku, Turku, Finland; Department of Pathology, Turku University Hospital, Turku, Finland. Electronic address: pekka.taimen@utu.fi.

Classifications MeSH